TSN084 Treating Patients With Advanced Malignant Tumors
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Tyligand Bioscience (Shanghai) Limited
- Target Recruit Count
- 114
- Registration Number
- NCT06386705
- Locations
- 🇨🇳
Peking university cancer hospital, Beijing, Beijing, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study of TSN1611 Treating Patients with Advanced Solid Tumors Harboring KRAS G12D Mutation
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Tyligand Pharmaceuticals (Suzhou) Limited
- Target Recruit Count
- 150
- Registration Number
- NCT06385925
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸NEXT Oncology, San Antonio, Texas, United States
🇺🇸NEXT Virginia, Fairfax, Virginia, United States
TSN222 in Subjects With Advanced Solid Tumors or Lymphomas
Phase 1
Recruiting
- Conditions
- Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma
- Interventions
- Drug: Phase II-Advanced melanomaDrug: Phase I dose escalationDrug: Phase II-HNSCCDrug: Phase II-solid tumors or lymphomas
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Tyligand Bioscience (Shanghai) Limited
- Target Recruit Count
- 162
- Registration Number
- NCT05842785
- Locations
- 🇨🇳
Fudan Cancer Hospital, Shanghai, Shanghai, China
Phase I Study of TSN084 in Patients With Advanced Malignant Tumors.
- First Posted Date
- 2022-03-29
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Tyligand Bioscience (Shanghai) Limited
- Target Recruit Count
- 74
- Registration Number
- NCT05300438
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath